Aura Biosciences, Inc.(AURA)Earnings, Financials & Key RatiosAura Biosciences, Inc. (AURA) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's current cash position of $84.8 million appears insufficient to cover the $34.9 million quarterly operating loss, suggesting a high probability of near-term dilutive financing.
Aura Biosciences, Inc. (AURA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Aura Biosciences, Inc. (AURA) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.50vs $0.40-25.0% | — |
| Q2 2026 | Mar 30, 2026 | $0.37vs $0.43+14.0% | — |
| Q4 2025 | Nov 13, 2025 | $0.40vs $0.46+13.0% | — |
| Q3 2025 | Aug 13, 2025 | $0.47vs $0.49+4.1% | — |
Recent stock market news and headlines for Aura Biosciences, Inc. (AURA)
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2026) - Auranova Resources Inc. (TSXV: AURA) ("Auranova" or the "Company") and Kenorland Minerals Ltd. ("Kenorland") are pleased to announce complete assay results from the 2026 spring (phase 3) diamond drill program at the South Uchi Project (the "Project"), located in the Red Lake District of Ontario.
Key metrics vs top competitors for Aura Biosciences, Inc. (AURA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.00 | $449.4M | -3.98 | — | — | -73.52% | — | |
| $9.84 | $2.15B | -6.93 | -18.67% | -558.24% | -64.55% | — | |
| $3.25 | $354.88M | -1.62 | — | — | -70.79% | — | |
| $4.36 | $96.26M | -0.66 | -72.22% | — | — | — | |
| $11.63 | $960.32M | -3.79 | — | — | -102.69% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — |
Aura Biosciences, Inc. (AURA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Aura Biosciences, Inc. (AURA) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 11, 2026·SEC
May 5, 2026·SEC
May 4, 2026·SEC
Get notified when AURA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Aura Biosciences, Inc. (AURA) stock FAQ — growth, dividends, profitability & financials explained
Aura Biosciences, Inc. (AURA) reported a net loss of $112.4M for fiscal year 2025.
Aura Biosciences, Inc. (AURA) has a return on equity (ROE) of -73.5%. Negative ROE indicates the company is unprofitable.
Aura Biosciences, Inc. (AURA) had negative free cash flow of $91.6M in fiscal year 2025, likely due to heavy capital investments.
